Table 2.
Patients and the tumor characteristics of CRC adenocarcinoma in FFPE, fresh tissue and plasma studies. *N/A: Not applicable.
| Type | Biological FFPE tissue validation | Biological fresh tissue validation | Tissue expression | Plasma study | ||||
|---|---|---|---|---|---|---|---|---|
| Cases | Control | Cases | Control | Cases | Control | Cases | Control | |
| Number | (N = 39) | (N = 47) | (N = 28) | (N = 26) | (N = 33) | (N = 35) | (N = 22) | (N = 20) |
| Gender | ||||||||
| Male | 23 (59%) | 27 (57%) | 19 (68%) | 18 (69) | 19 (57%) | 17 (48%) | 13 (59%) | 11(55%) |
| Female | 16 (41%) | 20 (43%) | 9 (32%) | 8 (31) | 14 (43) | 18 (52%) | 9 (41%) | 9 (45%) |
| Age at Diagnosis (Year) | ||||||||
| Median | 58 | 61 | 67 | 59 | 59 | 56 | 67 | 56 |
| Range | [24–85] | [24–85] | [44–82] | [45–84] | [24–85] | [35–77] | [44–82] | [45–84] |
| Tumor site | ||||||||
| Anal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Rectum | 3 (8%) | 4 (8%) | 10 (36%) | 9 (35%) | 2 (6%) | 0 | 8 (36%) | — |
| Sigmoid | 20(51%) | 24 (51%) | 6 (21%) | 12 (46%) | 18 (54%) | 21 (60%) | 4 (18%) | — |
| Transverse colon | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Descending colon | 4 (10%) | 5 (11%) | 1 (3%) | 0 | 3 (9%) | 7 (20%) | 1 (5%) | — |
| Ascending colon | 7 (18%) | 7 (15%) | 3 (11%) | 1 (4%) | 5 (15%) | 0 | 3 (14%) | — |
| Cecum | 2 (5%) | 2 (4%) | 8 (29%) | 4 (15%) | 2 (6%) | 0 | 6 (27%) | — |
| Entire colon | 3 (8%) | 5 (11%) | 0 | 0 | 3 (9%) | 7 (20%) | 0 | — |
| TNM stage | ||||||||
| I | 7 (18%) | — | N/A | — | 6 (18%) | — | N/A | — |
| IIA | 8 (21%) | — | N/A | — | 6 (18%) | — | N/A | — |
| IIB | 2 (5%) | — | N/A | — | 2 (6%) | — | N/A | — |
| IIC | 1 (2%) | — | N/A | — | 1 (3%) | — | N/A | — |
| IIIA | 2 (5%) | — | N/A | — | 2 (6%) | — | N/A | — |
| IIIB | 10 (26%) | — | N/A | — | 7 (21%) | — | N/A | — |
| IIIC | 9 (23%) | — | N/A | — | 9 (27%) | — | N/A | — |
| IVA | 0 | — | N/A | — | 0 | — | N/A | — |
| IVB | 0 | — | N/A | — | 0 | — | N/A | — |
| Tumor size | ||||||||
| ≥4 | 15 (39%) | — | N/A | — | 10 (30%) | — | N/A | — |
| 4.1–7.9 | 20 (51%) | — | N/A | — | 20 (61%) | — | N/A | — |
| 8–11.9 | 2 (5%) | — | N/A | — | 1 (3%) | — | N/A | — |
| ≤12 cm | 2 (5%) | — | N/A | — | 2 (6%) | — | N/A | — |
| Mean of Cq | 29.7 | 35.5 | 29.7 | 35 | 32.5 | 27.8 | 36.3 | 0 |
| KRAS mutation | 19 (49%) | — | 9 (32%) | — | 12 (36%) | — | 6 (27%) | — |
| BRAF mutation | 9 (23%) | — | 3 (11%) | — | 5 (15%) | — | 2 (9%) | — |
| Diagnostic | ||||||||
| Sensitivity | 87% | 82% | — | 41% | ||||
| Specificity | 100% | 92% | — | 100% | ||||